1 min read
Wells Fargo Upgrades Zimmer Biomet, Citing Monogram Robot’s Revenue Tailwinds
The bank raised its rating to Overweight from Equal Weight, pointing to the company’s Monogram orthopedic robot.

Zimmer Biomet received a higher stock rating from Wells Fargo on Tuesday, with the bank pointing to its Monogram orthopedic robot as a source of revenue tailwinds.
The upgrade moved Wells Fargo’s rating on the company from Equal Weight to Overweight. The bank highlighted the robot in explaining its decision.
Zimmer Biomet acquired Monogram Technologies for $177 million in 2025. The Food and Drug Administration (FDA) has cleared the technology, which is semi-autonomous.